Posts filtered by tags: Biotech[x]


 

A second potential COVID-19 vaccine, backed by Bill and Melinda Gates, is entering human testing

A new COVID-19 vaccine candidate is entering Phase 1 clinical human testing today, after the U.S. Food and Drug Administration (FDA) accepted an application from Inovio Pharmaceuticals under the regulator’s Investigational New Drug program. Inovio plans to inject its first volunteer test subject with the INO-4800 DNA vaccine candidate it has developed, following promising results from preclinical studies performed on animals that did indicate increased immune response. The Inovio DNA vaccine can...
Tags: Health, TC, Medicine, Tech, Pennsylvania, Vaccination, Philadelphia, University of Pennsylvania, Vaccine, Bill, Biotech, Vaccines, Kansas City, Melinda Gates, U S Food and Drug Administration FDA, Perelman School of Medicine


GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months

GlaxoSmithKline has agreed to invest $250 million in infectious disease specialist Vir Biotechnology to launch a COVID-19 R&D alliance that the companies say could advance two experimental therapies to clinical testing this summer.The partnership will leverage antibody technology from Vir (NASDAQ: VIR) and genomics expertise from GSK (NYSE: GSK). The companies will work together to develop drugs and vaccines for the novel coronavirus. According to financial terms of the preliminary agreement, G...
Tags: Deals, Ebola, San Francisco, Trends, Investing, National Institutes of Health, GlaxoSmithKline, Biotech, Vaccines, Malaria, Life Sciences, GSK, Vir, Alnylam Pharmaceuticals, National blog main, Boston blog main


Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies

Fate Therapeutics has signed an agreement with Janssen Biotech to develop new cancer cell therapies that are derived from stem cells and landed $100 million up front as part of the global collaboration deal.The San Diego-based biotech has built a pipeline of experimental cell therapies that use induced pluripotent stem cells (iPSCs) to create chimeric antigen receptor (CAR) T-cell and CAR natural killer (NK) cell treatments. Fate (NASDAQ: FATE) has used iPSCs to make clonal cell lines that it l...
Tags: Deals, Cancer, Trends, Stem Cells, Collaboration, San Diego, Immunotherapy, Biotech, Life Sciences, Agreement, Clinical Trials, Janssen, Janssen Biotech, National blog main, National top stories, San Diego blog main


Sleep apnea retrofit designed by doctors and engineers could help address ventilator shortage

The FDA has been working to adapt its policies and restrictions to respond to the growing need for unconventional solutions like shortages of medical equipment needed for treating COVID-19 patients. A group of doctors, engineers and medical researchers from UC Berkeley, UCSF and working hospitals has devised a creative solution to the ventilator shortage they’re hoping will meet FDA standards for emergency use authorization (EUA), working with readily available hardware and a stockpile of medica...
Tags: Health, TC, Hardware, Medicine, Tech, Fda, Biotech, Uc-berkeley, Bay Area, EUA, CPAP, Sleep Apnea, Snoring, Coronavirus, COVID-19, UC Berkeley UCSF


Emergent BioSolutions gets $14.5M in federal funding to expedite COVID-19 plasma therapy development

Last week, we spoke to the Head of Emergent BioSolutions’ Therapeutics Business Unit Dr. Laura Saward about her company’s work developing plasma-based potential treatments for COVID-19. Now, the company announced that it has received $14.5 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), which is part of the U.S. Department of Health and Human Services (HHS), to speed the development of one of its treatment candidates. Emergent BioSolutions has been ...
Tags: Health, TC, Medicine, Anatomy, Funding, Tech, Biotech, Plasma, Head, BARDA, U S Department of Health and Human Services HHS, Coronavirus, COVID-19, COVID, Laura Saward, Emergent BioSolutions


VenBio Partners Bags $394M to Back More Medicine-Making Biotechs

Investors worried about a recession like venBio Partners’ risk-mitigated approach to venture capital investing. That approach has led new limited partners to join earlier backers in putting nearly $400 million into the San Francisco-based firm’s new fund.VenBio announced Friday it closed its third fund, raising $394 million which it plans to invest using the same guidelines that led it to back 29 biotechs since its inception in 2011.Corey Goodman, venBio co-founder and partner, in 2014 told Xco...
Tags: Startups, Boston, Funding, San Francisco, Trends, Investment, Venture Capital, M&a, Pfizer, Biotech, Financing, Life Sciences, Corey Goodman, National blog main, Boston blog main, Xconomy


Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More

The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3 billion.ARCH Venture Partners led the pack, adding two funds totaling $1.46 billion to its war chest. Flagship Pioneering bagged $1.1 billion, and venBio Partners reeled in $394 million. Flagship CEO Noubar Afeyan told Xconomy that the pandemic  unexpectedly highlights the need for investment in one of its new thematic areas of interest: “health ...
Tags: Startups, Cancer, Trends, Investment, Venture Capital, National, Novartis, Biotech, Venture Partners, Life Sciences, Abbott, Reata Pharmaceuticals, Amgen, Corey Goodman, Medtronic, Vir


In the wake of COVID-19, UK puts up £20M in grants to develop resilient tech for critical industries

Most of the world — despite the canaries in the coal mine — was unprepared to cope with the coronavirus outbreak that’s now besieging us. Now, work is starting to get underway both to help manage what is going on now and better prepare us in the future. In the latest development, the UK government today announced that it will issue £20 million ($24.5 million) in grants of up to £50,000 each to startups and other businesses that are developing tools to improve resilience for critical industries —...
Tags: Food, Startups, TC, Cloud, Ecommerce, Europe, UK, Enterprise, Education, Entertainment, Government, Collaborative Consumption, Funding, Policy, Automotive, Biotech


In the wake of COVID-19, UK puts up £20M in grants to develop resilience tech for critical industries

Most of the world — despite the canaries in the coal mine — was unprepared to cope with the coronavirus outbreak that’s now besieging us. Now, work is starting to get underway both to help manage what is going on now and better prepare us in the future. In the latest development, the UK government today announced that it will issue £20 million ($24.5 million) in grants of up to £50,000 each to startups and other businesses that are developing tools to improve resilience for critical industries —...
Tags: Food, TC, Cloud, Ecommerce, Europe, UK, Enterprise, Education, Entertainment, Government, Collaborative Consumption, Funding, Tech, Policy, Automotive, Biotech


Flagship Adds $1.1B for New Meds, More AI, & “Health Security”

Flagship Pioneering founder and CEO Noubar Afeyan didn’t know a global pandemic was in the cards for 2020 when he and his team laid out three new thematic areas of focus for the company last fall.One proved eerily prescient: The notion of “health security,” or the development of new products and therapies to treat health concerns before they arise or escalate. On Thursday the Cambridge, MA-based venture capital firm, best known for starting and spinning out biotechs, announced it had added $1.1...
Tags: Startups, Funding, Trends, Investment, Venture Capital, Machine Learning, National, Ai, Biotech, Financing, National Venture Capital Association, Illumina, Life Sciences, Clinical Trials, ARCH Venture Partners, Cambridge MA


Henry Ford Health System to conduct first large US study of hydroxychloroquine’s ability to prevent COVID-19

Despite false assertions by the president to the contrary, any potential treatments to counter or prevent COVID-19 are still only at the stage of early investigations, which include one-off treatment with special individual case authorizations, and small-scale clinical examinations. Nothing so far has approached the level of scrutiny needed to actually say anything definitively about their actual ability to treat COVID-19 or the SARS-CoV-2 virus that causes it, but the first large-scale U.S. cli...
Tags: Health, TC, Science, Medicine, France, White House, China, US, Tech, United States, Healthcare, Disease, Fda, Biotech, Anthony Fauci, Henry Ford


Henry Ford Health System to conduct first large U.S. study of hydroxychloroquine’s ability to prevent COVID-19

Despite false assertions by the President to the contrary, any potential treatments to counter or prevent COVID-19 are still only at the stage of early investigations, which include one-off treatment with special individual case authorizations, and small-scale clinical examinations. Nothing so far has approached the level of scrutiny needed to actually say anything definitively about their actual ability to treat COVID-19 or the SARS-CoV-2 virus that causes it, but the first large-scale U.S. cli...
Tags: Health, TC, Science, Medicine, France, White House, China, Tech, United States, President, Healthcare, Disease, Fda, Biotech, Anthony Fauci, Henry Ford


Forward launches ‘Forward At Home’ primary care service to address COVID-19 healthcare crunch

The global coronavirus pandemic has already caused a tremendous strain on healthcare resources around the world, and it’s leading to a shift in how healthcare is offered. Startup Forward, which debuted in 2016 and has since expanded its tech-focused primary care medical practice to locations in major cities across the U.S., is launching a new initiative called ‘Forward At Home’ that reflects those changes and adapts its care model accordingly. Forward’s primary differentiator is its focus on ...
Tags: Travel, Health, Google, Startups, TC, Cdc, China, Articles, Tesla, Ceo, United States, Healthcare, Biotech, Telemedicine, Aoun, Telehealth


ImmunityBio and Microsoft team up to precisely model how key COVID-19 protein leads to infection

An undertaking that involved combining massive amounts of graphics processing power could provide key leverage for researchers looking to develop potential cures and treatments for the novel coronavirus behind the current global pandemic. Immunotherapy startup ImmunityBio is working with Microsoft’s Azure to deliver a combined 24 petaflops of GPU computing capability for the purposes of modelling, in a very high degree of detail, the structure o the so-called “spike protein” that allows the SARS...
Tags: Health, TC, Science, Microsoft, Tech, Nvidia, Vaccination, Machine Learning, Vaccine, Biotech, Viruses, Gpu, Coronavirus, COVID-19, ImmunityBio


Researchers to study if startup’s wrist-worn wearable can detect early COVID-19 respiratory issues

It’s highly unlikely that the current coronavirus crisis will neatly and fully “solved” by any one endeavor or solution, which makes news studies like one involving startup WHOOP’s wrist-worn fitness and health tracking wearable all the more important. The study, conducted by the Central Queensland University Australia (CQUniversity), in partnership with the Cleveland Clinic, will employ data collected WHOOP’s hardware with hundreds of volunteers who have self-identified as having contracted COV...
Tags: Travel, Health, Startups, TC, Gadgets, Hardware, Fitness, Startup, Arizona, University Of Arizona, Biotech, Viruses, Whoop, UCSF, Cleveland Clinic, Coronavirus


Pandion Pulls In $80M as Ulcerative Colitis Drug Advances in Clinic

Pandion Therapeutics emerged in 2018 aiming to reach clinic trials in two years testing its biologic drugs in autoimmune and inflammatory disorders. The company now has $80 million to support a lead program in early-stage testing and a pipeline of potential treatments.Access Biotechnology and Boxer Capital led the Series B round of funding announced Wednesday.Pandion is developing drugs intended to treat autoimmune diseases by fixing the immune system imbalance that leads to these conditions. T...
Tags: Deals, Startups, Boston, Trends, Investing, Ulcerative Colitis, Venture Capital, Cambridge, Biotech, Life Sciences, Autoimmune Diseases, Polaris Partners, Clinical Trials, Roche, Versant Ventures, National blog main


FDA introduces a new program to expedite deployment of potential coronavirus treatments

The U.S. Food and Drug Administration (FDA) announced a new program today that’s designed to foster close collaboration between public and private organizations in order to “bring coronavirus treatments to market as fast as possible,” according to U.S. Department of Health & Human Services Secretary Alex Azar in a press release. The program, dubbed the “Coronavirus Treatment Acceleration Program, or CTAP, will see the FDA redeploy resources and personnel with an eye towards providing private ...
Tags: Health, TC, Tech, Food And Drug Administration, Fda, Biotech, U S Food and Drug Administration FDA, U S Department of Health Human Services, EUA, Alex Azar, CTAP, Coronavirus, COVID-19


Color is launching a high-capacity COVID-19 testing lab and will open-source its design and protocols

Genomics health technology startup Color is doing its part to address the global COVID-19 pandemic, and has detailed the steps it’s taking to support expansion of testing efforts in a new blog post and letter from CEO Othman Laraki on Tuesday. The efforts include development of a high-throughput lab that can process as many as 10,000 tests per day, with a turnaround time of within 24 hours for reporting results to physicians. In order to provide the most benefit possible from the effort of stand...
Tags: Health, Startups, TC, Science, Education, Tech, Mit, Harvard, Genomics, Biotech, Test, Cornell, Broad Institute, Weill Cornell Medicine, Color Genomics, Othman Laraki


Cue Health awarded $13 million government contract to develop portable, point-of-care COVID-19 test

Biotech startup Cue Health has secured a $13 million contract from the U.S. Department of Health and Human Service’ Biomedical Research and Development Authority (BARDA), which will be used to speed the development and testing of a handheld molecular test that can detect the presence of the SARS-CoV-2 novel coronavirus that causes COVID-19. Cue, which broke cover in 2014 with plans for a connected lab in a box for at-home testing and a $7.5 million funding round, is developing a product that pai...
Tags: Health, Startups, TC, Tech, Ceo, Fda, Biotech, Influenza, Viruses, BARDA, Pandemic, Coronavirus, COVID-19, COVID, Cue Health, Ayub Khattak


Leading VCs discuss how COVID-19 has impacted the world of digital health

In December 2019, Extra Crunch spoke to a group of investors leading the charge in health tech to discuss where they saw the most opportunity in the space leading into 2020. At the time, respondents highlighted startups in digital therapeutics, telehealth and mental health that were improving medical practitioner efficiency or streamlining the distribution of care, amongst a variety of other digital health markets that were garnering the most attention. Where top VCs are investing in digital h...
Tags: Health, Fundings & Exits, Startups, TC, Science, Funding, Medical, Tech, Policy, Mental Health, Healthcare, Venture Capital, Biotech, Telemedicine, Diagnosis, Kleiner Perkins


Tapping Into the Innovation Grid: J&J, Data, and a Shifting Healthcare Focus

Johnson & Johnson’s global head of external innovation says there needs to be a shift in how healthcare research is funded to focus on early detection and curing rather than managing diseases.“When you look at the investment in research in the pharma industry, it’s all designed to treat established diseases,” William Hait, global head of Johnson & Johnson (NYSE: JNJ) External Innovation, told delegates at the BIO-Europe Spring event, held digitally last week due to the coronavirus crisis.While ...
Tags: Apple, Deals, Startups, Wearables, Europe, Drugs, Big Data, Cancer, Trends, Tech, Data, Innovation, Venture Capital, Genomics, National, Biotech


Medtronic is sharing its portable ventilator design specifications and code for free to all

Healthcare and biomedical engineering company Medtronic, which was in the news recently because Tesla CEO Elon Musk had discussions with the company about the automaker’s potential plans to build ventilator hardware in order to , but today it’s doing something potentially far more impactful. Medtronic is making the full design specifications, produce manuals, design documents, and in the future, software code for its Puritan Bennett (PB) 560 portable ventilator hardware available to anyone. T...
Tags: Health, TC, Elon Musk, Science, Hardware, Medicine, Tech, Tesla, Ceo, Engineer, Devices, Healthcare, World Health Organization, Biotech, Dyson, Medtronic


Cell and gene therapy startup ElevateBio raises $170M

While economic conditions and the ongoing global coronavirus pandemic may not make for the best atmosphere for raising funding, some companies are still announcing round closures with significant money committed. Cambridge-based ElevateBio, for instance, revealed a $170 million Series B funding on Monday, with participation from new investors The Invus Group, Surveyor Capital, EDBI, and Vertex Ventures, along with existing investors F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group and Sams...
Tags: Health, Startups, TC, Science, Biology, Drugs, Massachusetts, Tech, Cambridge, Manufacturing, Biotech, Stem Cell, Pharma, Biotechnology, Life Sciences, Baylor College of Medicine


Cell and gene therapy startup ElevateBio raises $170 million

While economic conditions and the ongoing global coronavirus pandemic may not make for the best atmosphere for raising funding, some companies are still announcing round closures with significant money committed. Cambridge-based ElevateBio, for instance, revealed a $170 million Series B funding on Monday, with participation from new investors The Invus Group, Surveyor Capital, EDBI, and Vertex Ventures, along with existing investors F2 Ventures, MPM Capital, EcoR1 Capital, Redmile Group and Sams...
Tags: Health, Startups, TC, Science, Biology, Drugs, Massachusetts, Tech, Cambridge, Manufacturing, Biotech, Stem Cell, Pharma, Biotechnology, Life Sciences, Baylor College of Medicine


A new FDA-authorized COVID-19 test doesn’t need a lab and can produce results in just 5 minutes

There’s a new COVID-19 test from healthcare technology maker Abbott that looks to be the fastest yet in terms of producing results, and that can do so on the spot right at point-of-care, without requiring a round trip to a lab. This test for the novel coronavirus causing the current global pandemic has received emergency clearance for use by the U.S. Food and Drug Administration, and will begin production next week, with output of 50,000 per day possible starting next week. The new Abbott ID ...
Tags: Health, TC, Science, Medicine, Tech, United States, Healthcare, Food And Drug Administration, Fda, Biotech, Viruses, Infection, Abbott, Veterinary Medicine, U S Food and Drug Administration, Coronavirus


Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance

Sanofi is joining the array of companies pursuing a COVID-19 vaccine based on messenger RNA (mRNA), an experimental genetic technology intended to coax the body’s cells into producing proteins that treat a disease or spark immunity to one.Sanofi (NYSE: SNY) announced Friday that it will develop COVID-19 vaccine candidates with Translate Bio (NASDAQ: TBIO), a Lexington, MA-based developer of mRNA therapies. The companies are already partners. In 2018, they began a three-year alliance aiming to d...
Tags: Deals, Europe, Trends, Pfizer, Biotech, Vaccines, Life Sciences, Clinical Trials, Sanofi, Lexington, CureVac, Sanofi Pasteur, SNY, National blog main, Boston blog main, Boston top stories


Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More

Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible.Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials or postpone studies that have not yet started. Eli Lilly (NYSE: LLY) said that many healthcare systems are devoting their resources to treating COVID-19 patients, which makes it difficult for these sites to also start new...
Tags: Deals, Startups, Ipo, Trends, Investing, It, Software, Insomnia, Multiple Sclerosis, Astrazeneca, Fda, National, Type 2 Diabetes, Epilepsy, Pfizer, Parkinson's Disease


Frontiers launches a portal to help connect coronavirus and COVID-19 research with funding

Open science platform and publisher Frontiers wants to make sure that efforts by researchers to pursue science-based solutions to the global coronavirus pandemic, and learn more about the virus and the COVID-19 disease it causes, find the funding they need. They launched a new portal to do just that, which is updated daily, and lists open funding calls, including the grant type, deadline, organization behind it, and specific area it supports. Sources include governments, non-profits, and commerc...
Tags: Health, TC, Science, Tech, Research, Biotech, Viruses, Frontiers, Coronavirus, COVID-19, COVID


How one company is fast-tracking development of potential plasma-based treatments for the coronavirus

Medical biotech company Emergent BioSolutions is one of the many health industry players turning its efforts towards addressing the current global coronavirus pandemic. Their work includes a two-pronged effort to pursue plasma-based treatments that could help lessen the impact of COVID-19 on health care systems, with a fast-tracked development timeline that could see human clinical trials start as soon as this summer. The company is simultaneously working on two different therapeutic approaches,...
Tags: Health, TC, Science, Medicine, Tech, Food And Drug Administration, Fda, Manufacturing, Biotech, Infection, Head, Drug Development, Emergent, Saward, Coronavirus, COVID-19


AstraZeneca Joins RNAi Mix, Pledging $80M to Silence Therapeutics

After years of research, technology for silencing a gene—stopping it from producing a disease-causing protein—has reached patients. AstraZeneca is now angling for a position in this burgeoning field through an alliance with Silence Therapeutics, a biotech developing such gene-silencing drugs.According to deal terms announced Wednesday, AstraZeneca (NYSE: AZN) will pay London-based Silence (LON: SLN) $60 million up front. The pharmaceutical giant will also make a $20 million equity investment in...
Tags: Deals, Europe, London, Trends, Astrazeneca, Biotech, Life Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceuticals, SLN, Alnylam Pharmaceuticals, Takeda Pharmaceutical, National blog main, Boston blog main, National top stories, Boston top stories